FIELD: medicine.
SUBSTANCE: present invention relates to immunology. Antibody and a fragment thereof capable of binding to the epidermal growth factor receptor (EGFR) and containing hypervariable regions from the panitumumab antibody and the constant region of human IgG1 are provided. Also presented are: a nucleic acid molecule and a combination of nucleic acid molecules encoding antibody or fragment thereof; immunoconjugate and a pharmaceutical composition for treating or preventing diseases or disorders associated with abnormal EGFR expression. In addition, the use of antibody, a fragment thereof, a nucleic acid molecule, a combination of such molecules, immunoconjugate and a pharmaceutical composition in the manufacture of medicaments is discussed.
EFFECT: antibody as per present invention has optimal affinity for EGFR, improved biological and antitumor activity, and can therefore be used in cancer therapy.
14 cl, 5 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS OF RECOMBINANT ANTIBODIES FROM EPIDERMAL GROWTH FACTOR RECEPTOR | 2009 |
|
RU2540146C2 |
| BINDING MOLECULE SPECIFIC FOR HER3, AND THEIR APPLICATIONS | 2012 |
|
RU2620068C2 |
| COMPOSITION COMPRISING TWO ANTIBODIES ENGINEERED TO HAVE REDUCED AND INCREASED EFFECTOR FUNCTION | 2013 |
|
RU2650788C2 |
| MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS GITR | 2019 |
|
RU2734432C1 |
| HUMANIZED ANTI-SIRPα ANTIBODIES | 2019 |
|
RU2812199C2 |
| METHOD OF DESTROYING CELLS USING EFFECTOR FUNCTIONS OF ANTI-EphA4 ANTIBODIES | 2007 |
|
RU2429246C2 |
| TARGETED/IMMUNOMODULATING FUSION PROTEINS AND METHODS FOR THEIR OBTAINING | 2013 |
|
RU2636342C2 |
| BISPECIFIC ANTIBODIES | 2011 |
|
RU2573588C2 |
| CANCER TREATMENT USING ANTI-NKG2A AGENTS | 2015 |
|
RU2721271C2 |
| POLYSPECIFIC ANTIBODIES CONTAINING ANTIBODY OF FULL LENGTH AND ONE-CHAIN FRAGMENTS FAB | 2010 |
|
RU2598248C2 |
